[go: up one dir, main page]

BRPI0517965A - compostos restritos como antagonistas de receptor de cgrp - Google Patents

compostos restritos como antagonistas de receptor de cgrp

Info

Publication number
BRPI0517965A
BRPI0517965A BRPI0517965-3A BRPI0517965A BRPI0517965A BR PI0517965 A BRPI0517965 A BR PI0517965A BR PI0517965 A BRPI0517965 A BR PI0517965A BR PI0517965 A BRPI0517965 A BR PI0517965A
Authority
BR
Brazil
Prior art keywords
receptor antagonists
cgrp
restricted
cgrp receptor
methods
Prior art date
Application number
BRPI0517965-3A
Other languages
English (en)
Inventor
Prasad V Chaturvedula
Stephen E Mercer
Haiquan Fang
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BRPI0517965A publication Critical patent/BRPI0517965A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

COMPOSTOS RESTRITOS COMO ANTAGONISTAS DE RECEPTOR DE CGRP. A invenção abrange antagonistas de receptor de CGRP bicíclicos e tricíclicos restritos, métodos para a identificação deles, composições farmacêuticas compreendendo-os, e métodos para seu emprego em terapia para tratamento de enxaqueca e outras cefalélas, vasodilatação neurogênica, inflamação neurogênica, lesão térmica, choque circulatório, rubor associadocom meno pausa, doenças inflamatórias das vias aéreas, tais como asma e doença pulmonar obstrutiva crónica (COPD), e outras condições cujo tratamento pode ser realizado pelo antagonismo de receptores de CGRP.
BRPI0517965-3A 2004-11-03 2005-10-12 compostos restritos como antagonistas de receptor de cgrp BRPI0517965A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US62465504P 2004-11-03 2004-11-03
US67809905P 2005-05-05 2005-05-05
US11/247,697 US7384930B2 (en) 2004-11-03 2005-10-11 Constrained compounds as CGRP-receptor antagonists
PCT/US2005/036859 WO2006052378A1 (en) 2004-11-03 2005-10-12 Constrained compounds as cgrp-receptor antagonists

Publications (1)

Publication Number Publication Date
BRPI0517965A true BRPI0517965A (pt) 2008-10-28

Family

ID=36262864

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0517965-3A BRPI0517965A (pt) 2004-11-03 2005-10-12 compostos restritos como antagonistas de receptor de cgrp

Country Status (14)

Country Link
US (2) US7384930B2 (pt)
EP (1) EP1809633A1 (pt)
JP (1) JP2008519074A (pt)
KR (1) KR20070085647A (pt)
AR (1) AR051755A1 (pt)
AU (1) AU2005305245A1 (pt)
BR (1) BRPI0517965A (pt)
CA (1) CA2586370A1 (pt)
IL (1) IL182828A0 (pt)
MX (1) MX2007005119A (pt)
NO (1) NO20072188L (pt)
PE (1) PE20060722A1 (pt)
TW (1) TW200628470A (pt)
WO (1) WO2006052378A1 (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7220862B2 (en) * 2002-06-05 2007-05-22 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
US7842808B2 (en) * 2002-06-05 2010-11-30 Bristol-Myers Squibb Company Anti-migraine spirocycles
BRPI0311812B8 (pt) * 2002-06-05 2021-05-25 Bristol Myers Squibb Co antagonistas de receptor de peptídeo relacionado com o gene de calcitonina, composição farmacêutica e seu uso
TW200524601A (en) * 2003-12-05 2005-08-01 Bristol Myers Squibb Co Heterocyclic anti-migraine agents
TW200533398A (en) * 2004-03-29 2005-10-16 Bristol Myers Squibb Co Novel therapeutic agents for the treatment of migraine
US7384931B2 (en) * 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7384930B2 (en) * 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7879591B2 (en) * 2004-11-04 2011-02-01 E.I. Du Pont De Nemours And Company High eicosapentaenoic acid producing strains of Yarrowia lipolytica
US7449586B2 (en) * 2004-12-03 2008-11-11 Bristol-Myers Squibb Company Processes for the preparation of CGRP-receptor antagonists and intermediates thereof
GB0515323D0 (en) 2005-07-26 2005-08-31 Electrophoretics Ltd Mass labels
US7834007B2 (en) * 2005-08-25 2010-11-16 Bristol-Myers Squibb Company CGRP antagonists
RS20080200A (sr) 2005-11-14 2009-07-15 Rinat Neuroscience Corp., Antagonistička antitela usmerena protiv kalcitonina, peptida povezanog sa genom, i postupak njihovog korišćenja
US8071770B2 (en) 2005-11-18 2011-12-06 Merck Sharp & Dohme Corp. Spirohydantoin aryl CGRP receptor antagonists
EP1954135B1 (en) * 2005-11-18 2012-10-10 Merck Sharp & Dohme Corp. Spirolactam aryl cgrp receptor antagonists
WO2007061692A2 (en) * 2005-11-18 2007-05-31 Merck & Co., Inc. Spirolactam tricyclic cgrp receptor antagonists
WO2007061694A2 (en) 2005-11-18 2007-05-31 Merck & Co., Inc. Spirohydantoin tricyclic cgrp receptor antagonists
US7470679B2 (en) * 2006-05-02 2008-12-30 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7470680B2 (en) * 2006-05-03 2008-12-30 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
WO2008011190A1 (en) * 2006-07-21 2008-01-24 Vertex Pharmaceuticals Incorporated Cgrp receptor antagonists
WO2008070014A2 (en) * 2006-12-04 2008-06-12 Neurogen Corporation Biaryl ketone-substituted piperidines
US7951795B2 (en) * 2006-12-08 2011-05-31 Merck Sharp & Dohme Corp. Constrained spirocyclic compounds as CGRP receptor antagonists
CA2672230A1 (en) * 2006-12-20 2008-07-17 Merck & Co., Inc. Benzazepine compounds as cgrp receptor antagonists
JP2011512410A (ja) * 2008-02-19 2011-04-21 メルク・シャープ・エンド・ドーム・コーポレイション イミダゾベンゾアゼピンｃｇｒｐ受容体アンタゴニスト
US8293239B2 (en) 2008-03-04 2012-10-23 Pfizer Limited Methods of treating chronic pain
US8044043B2 (en) * 2008-04-11 2011-10-25 Bristol-Myers Squibb Company CGRP receptor antagonists
CA2771186C (en) 2009-08-28 2018-01-02 Rinat Neuroscience Corporation Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide
US20140005214A1 (en) * 2011-03-18 2014-01-02 Ian M. Bell Piperidinone carboxamide spirohydantoin cgrp receptor antagonists
US8748429B2 (en) * 2011-04-12 2014-06-10 Bristol-Myers Squibb Company CGRP receptor antagonists
MX365784B (es) 2011-04-21 2019-05-28 Origenis Gmbh Compuestos heterociclicos como inhibidores de cinasas.
US10000482B2 (en) 2012-10-19 2018-06-19 Origenis Gmbh Kinase inhibitors
CN105636586B (zh) 2013-10-03 2018-05-29 库拉肿瘤学公司 Erk抑制剂及使用方法
KR102274964B1 (ko) 2014-03-21 2021-07-09 테바 파마슈티컬스 인터내셔널 게엠베하 칼시토닌 유전자-관련 펩티드에 대한 길항제 항체 및 그의 사용 방법
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
US10287337B2 (en) * 2015-06-01 2019-05-14 Afasci, Inc. Compositions and methods for treating acute and chronic pain by local antagonism of CGRP receptors, or combination with sodium channel inhibition or with anti-inflammatory agents
FI3515937T3 (fi) 2016-09-23 2026-02-11 Teva Pharmaceuticals Int Gmbh Refraktaarisen migreenin hoito
EP3366286A1 (en) 2017-02-22 2018-08-29 Johannes Keller Compounds for treating sepsis
KR20220079882A (ko) * 2019-10-07 2022-06-14 디.이. 쇼우 리서치, 엘엘씨 Kv1.3 칼륨 셰이커 채널 차단제로서의 아릴 헤테로시클릭 화합물
CN118666833B (zh) * 2024-05-30 2024-12-13 龙曦宁（上海）医药科技有限公司 一种2-（5-溴吡啶-3-基）奎宁环的制备方法

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0851759A4 (en) 1995-09-05 2000-12-06 Smithkline Beecham Corp COMPOUNDS AND RELATED METHODS
WO1998009630A1 (en) 1996-09-09 1998-03-12 Smithkline Beecham Corporation Compounds and methods
ATE266673T1 (de) * 1996-09-10 2004-05-15 Boehringer Ingelheim Pharma Abgewandelte aminosäuren, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
WO1998056779A1 (en) 1997-06-13 1998-12-17 Smithkline Beecham Corporation 4-sulfinyl benzamides as calcitonin gene-related peptide receptor antagonists
US20030069231A1 (en) * 1999-10-12 2003-04-10 Klaus Rudolf Modified aminoacids, pharmaceuticals containing these compounds and method for their production
EP1070054A1 (en) 1998-04-08 2001-01-24 Takeda Chemical Industries, Ltd. Amine compounds, their production and their use as somatostatin receptor antagonists or agonists
JP2002525371A (ja) * 1998-09-30 2002-08-13 メルク シャープ エンド ドーム リミテッド Ｃｇｒｐリガンドとしてのベンゾイミダゾリニルピペリジン
DE19911039A1 (de) 1999-03-12 2000-09-14 Boehringer Ingelheim Pharma Abgewandelte Aminosäureamide, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US6313097B1 (en) * 1999-03-02 2001-11-06 Boehringer Ingelheim Pharma Kg Antagonists of calcitonin gene-related peptide
US6521609B1 (en) * 1999-08-10 2003-02-18 Boehringer Ingelheim Pharma Kg Use of CGRP antagonists and CGRP release inhibitors for combating menopausal hot flushes
CA2386517A1 (en) 1999-10-07 2001-04-12 Takeda Chemical Industries, Ltd. Amine derivatives
DE19952147A1 (de) 1999-10-29 2001-05-03 Boehringer Ingelheim Pharma Neue Cyclopropane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE19952146A1 (de) 1999-10-29 2001-06-07 Boehringer Ingelheim Pharma Arylalkane, Arylalkene und Aryl-azaalkane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE19963868A1 (de) * 1999-12-30 2001-07-12 Boehringer Ingelheim Pharma Neue substituierte Piperidine, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
AR035040A1 (es) 2000-08-01 2004-04-14 Sod Conseils Rech Applic Derivados de imidazolilo, composiciones farmaceuticas que los comprenden y el uso de los mismos para la preparacion de medicamentos capaces de unir selectivamente a los subtipos del receptor de somatostatina
US20030181462A1 (en) * 2001-08-17 2003-09-25 Boehringer Ingelheim Pharma Kg Use of BIBN4096 in combination with other antimigraine drugs for the treatment of migraine
ATE453661T1 (de) 2001-09-27 2010-01-15 Merck & Co Inc Isolierte dna-moleküle, die für einen humanisierten calcitonin gene-related peptide receptor kodieren, damit verwandte, nichthumane transgene tiere und assayverfahren
US6900317B2 (en) * 2002-02-19 2005-05-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Salts of the CGRP antagonist BIBN4096 and inhalable powdered medicaments containing them
DE10206770A1 (de) 2002-02-19 2003-08-28 Boehringer Ingelheim Pharma Verfahren zur Herstellung eines Pulverinhalativums enthaltend ein Salz des CGRP-Antagonisten BIBN4096
US20040014679A1 (en) * 2002-02-20 2004-01-22 Boehringer Ingelheim Pharma Gmbh & Co., Kg Inhalation powder containing the CGRP antagonist BIBN4096 and process for the preparation thereof
US7026312B2 (en) * 2002-03-14 2006-04-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
DE10211770A1 (de) 2002-03-14 2003-10-02 Boehringer Ingelheim Pharma Neue substituierte Piperidine, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US7057046B2 (en) * 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
BRPI0311812B8 (pt) * 2002-06-05 2021-05-25 Bristol Myers Squibb Co antagonistas de receptor de peptídeo relacionado com o gene de calcitonina, composição farmacêutica e seu uso
US7220862B2 (en) * 2002-06-05 2007-05-22 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
US20040076587A1 (en) * 2002-06-19 2004-04-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical composition for intranasal administration containing a CGRP antagonist
CA2489560A1 (en) 2002-06-27 2004-01-08 Schering Aktiengesellschaft Substituted quinoline ccr5 receptor antagonists
DE10250080A1 (de) 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE10250082A1 (de) * 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE10300973A1 (de) * 2003-01-14 2004-07-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Carbonsäuren und deren Ester, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
EP1606286B1 (en) 2003-03-14 2011-05-11 Merck Sharp & Dohme Corp. Benodiazepine spirohydantoin cgrp receptor antagonists
EP1605936B1 (en) 2003-03-14 2011-07-20 Merck Sharp & Dohme Corp. Aryl spirohydantoin cgrp receptor antagonists
JP4673295B2 (ja) 2003-03-14 2011-04-20 メルク・シャープ・エンド・ドーム・コーポレイション 単環式アニリドスピロヒダントインｃｇｒｐ受容体拮抗物質
WO2004082605A2 (en) 2003-03-14 2004-09-30 Merck & Co. Inc. Bicyclic anilide spirohydantoin cgrp receptor antagonists
WO2004082602A2 (en) 2003-03-14 2004-09-30 Merck & Co. Inc. Carboxamide spirohydantoin cgrp receptor antagonists
US20040248816A1 (en) * 2003-04-01 2004-12-09 Boehringer Ingelheim International Gmbh Treatment of migraine
EP1615914B1 (en) 2003-04-15 2010-05-05 Merck Sharp & Dohme Corp. Cgrp receptor antagonists
JO2355B1 (en) 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
EP1641781B1 (en) 2003-06-26 2013-03-06 Merck Sharp & Dohme Corp. Benzodiazepine CGRP receptor antagonists
ATE461196T1 (de) 2003-06-26 2010-04-15 Merck Sharp & Dohme Benzodiazepin-cgrp-rezeptor-antagonisten
US20050032783A1 (en) * 2003-07-07 2005-02-10 Boehringer Ingelheim International Gmbh Use of CGRP antagonists in treatment and prevention of hot flushes in prostate cancer patients
JP2007523870A (ja) 2003-07-15 2007-08-23 メルク　エンド　カムパニー　インコーポレーテッド ヒドロキシピリジンｃｇｒｐ受容体拮抗薬
US20050065094A1 (en) * 2003-09-05 2005-03-24 Boehringer Ingelheim International Gmbh Use of telmisartan for the prevention and treatment of vascular headache
CA2549330A1 (en) 2003-12-05 2005-07-21 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
TW200524601A (en) * 2003-12-05 2005-08-01 Bristol Myers Squibb Co Heterocyclic anti-migraine agents
US7491713B2 (en) 2004-01-29 2009-02-17 Merck + Co., Inc. CGRP receptor antagonists
WO2005084672A1 (de) 2004-03-03 2005-09-15 Boehringer Ingelheim International Gmbh Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
TW200533398A (en) * 2004-03-29 2005-10-16 Bristol Myers Squibb Co Novel therapeutic agents for the treatment of migraine
DE102004015723A1 (de) 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102004018796A1 (de) 2004-04-15 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102004018795A1 (de) 2004-04-15 2005-10-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7279471B2 (en) * 2004-04-15 2007-10-09 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
DE102004018794A1 (de) 2004-04-15 2005-10-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
WO2005102322A1 (de) 2004-04-20 2005-11-03 Boehringer Ingelheim International Gmbh Verwendung eines cgrp-antagonisten in kombination mit einem serotonin-wiederaufnahme-hemmer zur behandlung von migräne
US20050233980A1 (en) * 2004-04-20 2005-10-20 Boehringer Ingelheim International Gmbh CGRP-antagonist in combination with a serotonin-reuptake inhibitor for the treatment of migraine
DE102004019492A1 (de) 2004-04-22 2005-11-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7696195B2 (en) * 2004-04-22 2010-04-13 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
DE102004027912A1 (de) * 2004-06-09 2005-12-29 Grünenthal GmbH Substituierte Cyclopenten-Verbindungen
US7384930B2 (en) 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7449586B2 (en) 2004-12-03 2008-11-11 Bristol-Myers Squibb Company Processes for the preparation of CGRP-receptor antagonists and intermediates thereof
CA2672230A1 (en) 2006-12-20 2008-07-17 Merck & Co., Inc. Benzazepine compounds as cgrp receptor antagonists

Also Published As

Publication number Publication date
US7384930B2 (en) 2008-06-10
CA2586370A1 (en) 2006-05-18
KR20070085647A (ko) 2007-08-27
US20060094707A1 (en) 2006-05-04
JP2008519074A (ja) 2008-06-05
NO20072188L (no) 2007-07-19
US7544680B2 (en) 2009-06-09
US20080287422A1 (en) 2008-11-20
EP1809633A1 (en) 2007-07-25
IL182828A0 (en) 2007-08-19
TW200628470A (en) 2006-08-16
MX2007005119A (es) 2007-07-04
PE20060722A1 (es) 2006-08-16
WO2006052378A1 (en) 2006-05-18
AR051755A1 (es) 2007-02-07
AU2005305245A1 (en) 2006-05-18

Similar Documents

Publication Publication Date Title
BRPI0517965A (pt) compostos restritos como antagonistas de receptor de cgrp
BRPI0509341A (pt) anatagonistas de cgrp hetorocìclicos para o tratamento de enxaqueca
WO2007130860A3 (en) Constrained compounds as cgrp-receptor antagonists
BR0311812A (pt) Antagonistas de receptor de peptìdeo relacionado com o gene de calcitonina
CY1122121T1 (el) N-(5s,6s,9r)-5-amino-6-(2,3-διφθοpoφainyλ)-6,7,8,9-tetpaϋδpo-5h-κυκλοεπτα[β]πυριδιν-9-υλ-4-(2-οξο-2, 3-διϋδρο-1η-ιμιδαζο[4,5-β]πυριδιν-1-υλ)πιπεριδινο-1-καρβοξυλικο αλας
WO2005056550A3 (en) Heterocyclic anti-migraine agents
TN2012000139A1 (en) Cgrp receptor antagonists
BR0318637A (pt) antagonistas de receptores de peptìdios relacionados com o gene de calcitonina
WO2009126530A3 (en) Piperidine derivatives as cgrp receptor antagonists
ECSP077421A (es) Compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1
EA201100426A1 (ru) Бициклические ингибиторы киназы
EA200970302A1 (ru) Тиофенпиразолопиримидиновые соединения
EA201100427A1 (ru) Гетероциклические ингибиторы киназы
AR097388A1 (es) Beneficio de supervivencia en pacientes con tumores sólidos con niveles elevados de proteína c reactiva
NZ738778A (en) Pyrazolopyrimidine jak inhibitor compounds and methods
ATE517903T1 (de) Verbindungen mit eingeschränkter konformation als cgrp rezeptor antagonisten.
EA200800441A1 (ru) Замещенные бензимидазолы в качестве ингибиторов киназ
EP2328414A4 (en) SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES
PE20061391A1 (es) Anticuerpos para interleucina-17f y otros antagonistas de la senalizacion de il-17f
CL2008001593A1 (es) Compuestos derivados de heterociclos, antagonistas para el ccr2; y uso de los compuestos para tratar afecciones o enfermedades del tracto respiratorio, como enfermedad pulmonar obstructiva cronica y asma.
NO20085135L (no) Selektive inhibitorer av ROCK-proteinkinase og anvendelse derav
WO2007131020A3 (en) Constrained compounds as cgrp-receptor antagonists
ECSP088546A (es) Alquilsulfonamida-quinoleínas
CL2008000356A1 (es) Compuestos derivados de 4-amino quinazolina, capaces de inhibir la transduccion de senales a traves de pirosina quinasa; composicion farmaceutica que comprende uno de los compuestos; y procedimiento para preparar la composicion farmaceutica y los compuestos, utiles en el tratamiento tumores y enfermedades de las vias respiratorias y pulmonares.
GT200500332A (es) Azabenzoxazoles para el tratamiento de trastornos del snc

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]